NO20072466L - Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister - Google Patents

Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister

Info

Publication number
NO20072466L
NO20072466L NO20072466A NO20072466A NO20072466L NO 20072466 L NO20072466 L NO 20072466L NO 20072466 A NO20072466 A NO 20072466A NO 20072466 A NO20072466 A NO 20072466A NO 20072466 L NO20072466 L NO 20072466L
Authority
NO
Norway
Prior art keywords
receptor antagonists
preventing
adenosine receptor
respiratory
structural change
Prior art date
Application number
NO20072466A
Other languages
English (en)
Norwegian (no)
Inventor
Luiz Belardinelli
Dewan Zeng
Michael R Blackburn
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20072466L publication Critical patent/NO20072466L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20072466A 2004-10-15 2007-05-14 Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister NO20072466L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943904P 2004-10-15 2004-10-15
PCT/US2005/036950 WO2006044610A1 (en) 2004-10-15 2005-10-14 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20072466L true NO20072466L (no) 2007-05-14

Family

ID=35677798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072466A NO20072466L (no) 2004-10-15 2007-05-14 Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister

Country Status (13)

Country Link
US (2) US20060159627A1 (https=)
EP (2) EP1799221A1 (https=)
JP (2) JP2008516969A (https=)
KR (1) KR20070063548A (https=)
CN (1) CN101039677A (https=)
AU (1) AU2005295654B2 (https=)
CA (1) CA2583986A1 (https=)
IL (1) IL182493A0 (https=)
MX (1) MX2007004373A (https=)
NO (1) NO20072466L (https=)
NZ (2) NZ554485A (https=)
RU (1) RU2391103C2 (https=)
WO (1) WO2006044610A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
ES2557310T3 (es) * 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
EP1891070A1 (en) * 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
BR112012032766A2 (pt) * 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2016083304A1 (en) * 2014-11-24 2016-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r.
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP1208100B1 (en) * 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2400206A1 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DK1444233T3 (da) * 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
CN1620294A (zh) * 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
CA2544193C (en) 2003-10-31 2012-03-27 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
MX2007002437A (es) 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
EP1891070A1 (en) 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
AU2007227021B2 (en) 2006-03-17 2012-12-20 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
RU2007117907A (ru) 2008-11-20
JP2008516969A (ja) 2008-05-22
US20100105706A1 (en) 2010-04-29
AU2005295654B2 (en) 2011-04-14
WO2006044610A1 (en) 2006-04-27
KR20070063548A (ko) 2007-06-19
IL182493A0 (en) 2007-09-20
US8466129B2 (en) 2013-06-18
CA2583986A1 (en) 2006-04-27
EP2311462A1 (en) 2011-04-20
US20060159627A1 (en) 2006-07-20
CN101039677A (zh) 2007-09-19
JP2012056965A (ja) 2012-03-22
NZ589657A (en) 2012-06-29
NZ554485A (en) 2010-12-24
AU2005295654A1 (en) 2006-04-27
RU2391103C2 (ru) 2010-06-10
EP1799221A1 (en) 2007-06-27
MX2007004373A (es) 2007-08-08

Similar Documents

Publication Publication Date Title
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
BR0110946A (pt) Nova composição
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
NO20061254L (no) Farmasoytiske blandinger
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
MX2009001534A (es) Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva.
WO2012047674A3 (en) Methods and compositions for disease treatment using inhalation
WO2006117299A3 (en) Novel crystalline forms of tiotropium bromide
EP4591936A3 (en) Treatment of respiratory diseases
WO2010037066A3 (en) Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ590774A (en) Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
EA200801520A1 (ru) Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
EA200970158A1 (ru) Производные хинуклидина в качестве антагонистов м3
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
WO2009019598A3 (en) Inhalation therapy for respiratory disorders
WO2004043392A3 (en) Mucin synthesis inhibitors
DK1370264T3 (da) Nikotinreceptor-agonister til behndling af lungeinflammationssygdomme
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
EP2120935A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
AU2006329199A8 (en) Treatment of respiratory diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application